Ann: Race releases cardioprotection market potential data, page-84

We also should keep this in mind. "The peripheral (intravenous) formulation is critical for this specific opportunity in breast cancer
and as we look toward partnerships or potential licencing agreements in the future. The team is working on the formulation and updates on its progress are expected during H1 CY23" . Patient's comfort - as much as it can be - is also very important and could be a big selling point. Having a pill version - as long as it does the job the same way, if it can be done - would be a super bonus.